Charles River Laboratories International Inc $ 214.49 -2.87 (-1.32%)
Volume:
152,264
Avg Vol (1m):
376,373
Market Cap $:
10.66 Bil
Enterprise Value $:
12.69 Bil
P/E (TTM):
39.50
P/B:
6.08
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.17 | ||
| Equity-to-Asset | 0.33 | ||
| Debt-to-Equity | 1.39 | ||
| Debt-to-EBITDA | 4.05 | ||
| Interest Coverage | 5.78 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 2.85 | ||
| Beneish M-Score | -2.77 | ||
| WACC vs ROIC | |||
Profitability Rank | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 13.56 | ||
| Net Margin % | 9.87 | ||
| ROE % | 16.9 | ||
| ROA % | 5.57 | ||
| ROC (Joel Greenblatt) % | 31.05 | ||
| 3-Year Revenue Growth Rate | 14.6 | ||
| 3-Year EBITDA Growth Rate | 12.9 | ||
| 3-Year EPS without NRI Growth Rate | 16.3 |
Valuation Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 39.52 | ||
| Forward PE Ratio | 31.63 | ||
| PE Ratio without NRI | 39.52 | ||
| Price-to-Owner-Earnings | 24.26 | ||
| PB Ratio | 6.08 | ||
| PS Ratio | 3.91 | ||
| Price-to-Free-Cash-Flow | 25.77 | ||
| Price-to-Operating-Cash-Flow | 18.87 | ||
| EV-to-EBIT | 33.15 | ||
| EV-to-EBITDA | 21.12 | ||
| EV-to-Revenue | 4.63 | ||
| PEG Ratio | 2.72 | ||
| Shiller PE Ratio | 86.75 | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.46 | ||
| Days Inventory | 32.53 | ||
| Days Sales Outstanding | 53.56 | ||
| Days Payable | 17.25 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.93 | ||
| Price-to-Median-PS-Value | 1.55 | ||
| Price-to-Peter-Lynch-Fair-Value | 2.77 | ||
| Earnings Yield (Greenblatt) % | 2.99 | ||
| Forward Rate of Return (Yacktman) % | 17.05 |